샘플 요청 목록

 카트 문의
시장보고서
상품코드
1726210

C 반응성 단백질 검사 시장 규모, 점유율, 동향 분석 보고서 : 어세이 유형별, 검출 범위별, 질환 영역별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

C-Reactive Protein Testing Market Size, Share & Trends Analysis Report By Assay Type (ELISA, CLIA), By Detection Range (hs-CRP, Conventional CRP), By Disease Area, By End-use, By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 320 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

C 반응성 단백질 검사 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 C 반응성 단백질 검사 시장 규모는 2030년까지 56억 6,000만 달러에 달할 것으로 예상되고, 2025-2030년의 CAGR은 0.24%를 나타낼 것으로 예측됩니다.

C 반응성 단백질 검사의 성장은 검사의 다양한 응용을 탐구하는 것을 목표로 한 중요한 연구 활동으로 인한 것입니다. 헬스케어의 진보로 시장은 현저한 성장을 이룰 것으로 예측됩니다. 이 진보는 높은 특이성, 감도, 신속한 응답 시간, 의료 현장에서의 정확한 질환 진단 및 모니터링을 위한 다중화 능력 등의 특성을 가지는 휴대용 생물분석을 개발하는 유망한 기회를 기재하고 있습니다.

이러한 진보는 예측 기간 동안 CRP 검사 수요를 촉진할 것으로 예측됩니다. 또한 전략적 거래와 개발 증가, 연구 개발에 대한 투자 증가가 성장을 가속하고 있습니다.에 대한 수요가 높아지고 있습니다. Abbott와 같은 선도적인 기업들은 특히 SARS-CoV-2 감염에 대한 CRP 검사를 위한 지원 도구를 제공하여 시장 성장에 기여하고 있습니다.

예를 들어, 2022년 7월, 블룸 다이아그노스틱스는 혈액 내 CRP 수준을 정량화하도록 설계된 반자동 검사 키트인 블룸 염증 검사를 발표했습니다. 이 단일 사용 키트는 신체의 염증을 감지하는 데 도움이 됩니다. 시장의 성장은 검사 시설의 설립에 의해 더욱 자극될 것으로 예측됩니다. 2021년 6월 Trivitron 의료는 COVID-19 진단을 위한 이동식 검사실을 발표하여 농촌, 도시, 원격지 등 인도의 다양한 지역에서 검사 서비스를 가능하게 했습니다. 이 고유의 검사실은 CRP, IL-6, D-이량체 등의 염증 마커의 CLIA/Elisa 검사, 신속 항원 검사, RT-PCR 검사, CLIA/Elisa 항체 검사 IgM과 IgG 등 다양한 검사를 제공합니다.

북미는 2022년 39.42%의 최대 수익 점유율을 차지했으며 심혈관 질환 유병률 증가, 꾸준한 제품 출시, 기존 시장 진출기업의 존재, 기술 진보, 정비된 의료 인프라에 의해 예측 기간 동안도 그 점유율을 유지할 것으로 예측됩니다. 아시아태평양은 2023-2030년에 걸쳐 가장 빠른 CAGR 0.49%를 나타낼 것으로 예측됩니다. 감염의 중증도를 결정하는 잠재적인 바이오마커인 CRP 검사에 대한 수요는 곧 증가할 것으로 예측됩니다. 세계의 산업에서 사업을 전개하는 주요 기업은 그 존재감을 유지하기 위해 제품 출시와 지리적 확대에 끊임없이 주력하고 있습니다.

C 반응성 단백질 검사 시장 보고서 하이라이트

  • 분석 유형별로 면역 탁도 분석 부문은 2024년에 48.5%의 최대 수익 점유율을 차지했습니다. 샘플에서 CRP 수준을 정확하게 검출하기 위한 광범위한 분석 범위를 제공하는 고감도, 자동화된, 비용 효과적인 면역 탁도 분석의 도입에 의한 것입니다.
  • 검출 범위별로는 2024년에는 hs-CRP 부문이 약 42.80%의 수익 점유율로 시장을 독점했습니다.
  • 질병 영역별로는 심혈관 질환 부문이 2024년 최대 시장 점유율을 차지했고 예측 기간을 통해 시장을 독점할 것으로 예측됩니다.
  • 특히 COVID-19의 팬데믹에 대응해 병원에서의 CRP 검사의 채용이 증가했기 때문에 병원의 최종 사용자 부문이 2024년 시장 점유율 28.0%로 우위를 차지했습니다.
  • 또한 만성 심장 질환과 암의 유병률이 증가함에 따라 시장은 성장을 이루고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 C 반응성 단백질 검사 시장 변수, 동향, 범위

  • 시장 소개/계통 전망
  • 시장 규모와 성장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • C 반응성 단백질 검사 시장 분석 도구
    • Porter's Five Forces 분석
    • PESTEL 분석

제4장 C 반응성 단백질 검사 시장 : 어세이 유형별, 추정 및 동향 분석

  • C 반응성 단백질 검사 시장 : 어세이 유형 변동 분석
  • 면역 탁도 분석 분석
    • 면역 탁도 분석 검정 시장(2018-2030년)
  • ELISA
    • ELISA 시장(2018-2030년)
    • 임상 ELISA
    • 비임상 ELISA
  • 화학발광 면역 분석
    • 화학발광 면역 분석 시장(2018-2030년)
  • 기타
    • 기타 시장(2018-2030년)

제5장 C 반응성 단백질 검사 시장 : 검출 범위별, 추정 및 동향 분석

  • C 반응성 단백질 검사 시장 : 검출 범위 변동 분석
  • 고감도 C 반응성 단백질(hs-CRP)
    • 고감도 C 반응성 단백질(hs-CRP) 시장(2018-2030년)
  • 기존 CRP
    • 기존 CRP 시장(2018-2030년)
  • 심장 CRP(cCRP)
    • 심장 CRP(cCRP) 시장(2018-2030년)

제6장 C 반응성 단백질 검사 시장 : 질환 영역별, 추정 및 동향 분석

  • C 반응성 단백질 검사 시장 : 질환 영역 변동 분석
  • 심혈관 질환
    • 심혈관 질환 시장(2018-2030년)
  • 암
    • 암 시장(2018-2030년)
  • 류마티스 관절염
    • 류마티스 관절염 시장(2018-2030년)
  • 염증성 장질환
    • 염증성 장질환 시장(2018-2030년)
  • 자궁내막증
    • 자궁내막증 시장(2018-2030년)
  • 루푸스
    • 루푸스 시장(2018-2030년)
  • 기타
    • 기타 시장(2018-2030년)

제7장 C 반응성 단백질 검사 시장 : 최종 용도별, 추정 및 동향 분석

  • C 반응성 단백질 검사 시장 : 최종 용도 변동 분석
  • 클리닉
    • 클리닉 시장(2018-2030년)
    • 의사 사무실
    • 소규모 클리닉
  • 병원
    • 병원 시장(2018-2030년)
    • 도시환경
    • 지방환경
  • 실험실
    • 실험실 시장(2018-2030년)
    • 도시환경
    • 지방환경
  • 생활 보조 의료 시설
    • 생활 보조 의료 시설 시장(2018-2030년)
    • 도시환경
    • 지방환경
  • 주거
    • 주거 시장(2018-2030년)
  • 기타
    • 기타 시장(2018-2030년)

제8장 C 반응성 단백질 검사 시장 : 지역별, 추정 및 동향 분석

  • C 반응성 단백질 검사 시장 점유율(지역별(2024년, 2030년), 100만 달러)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트

제9장 경쟁 구도

  • 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • 기업 분류
  • 기업 히트맵 분석
  • 기업 프로파일
  • Abbott
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Siemens Healthineers AG
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Danaher Corporation
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Quest Diagnostics
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Siemens Healthineers AG
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Abbott
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Merck KGaAA
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Zoetis
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • F. Hoffmann-La Roche AG
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Ortho Clinical Diagnostics
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Thermo Fisher Scientific, Inc.
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • HORIBA, Ltd
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Randox Laboratories Ltd.
    • 참가 기업 개요
    • 최근 동향/전략적 이니셔티브
  • Boditech Med, Inc.
    • 참가 기업 개요
    • 최근의 동향/전략적 이니셔티브
  • Aidian
    • 참가 기업 개요
    • 최근의 동향/전략적 이니셔티브
KTH 25.05.27

C-Reactive Protein Testing Market Growth & Trends:

The global C-reactive protein testing market size is expected to reach USD 5.66 billion by 2030 and is projected to grow at a CAGR of 0.24% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of C-reactive protein (CRP) testing can be attributed to significant research activities aimed at exploring various applications of testing. These research efforts are further facilitated by the presence of both private and public agencies that provide funding to expedite research in this field. The market is anticipated to witness significant growth owing to advancements in nanotechnological tools. These advancements offer promising opportunities to develop portable bioanalytical assays that possess attributes, such as high specificity, sensitivity, rapid response time, and the ability to perform multiplexing for accurate disease diagnosis and monitoring at the point of care.

These advancements are expected to drive the demand for CRP testing during the forecast period. Furthermore, an increase in strategic deals and developments, as well as higher investments in research and development has fueled the growth. The COVID-19 pandemic has had a considerable impact on the market, as CRP is considered a crucial biomarker for assessing the severity of infection and inflammation. As a result, there is an increased demand for services and products. Leading companies, such as Abbott, provide supportive tools for CRP testing specifically for SARS-CoV-2 infection, further contributing to market growth. Moreover, key players increased focus on product launches and developments in point-of-care CRP tests, which is projected to further fuel the market's growth in the coming years.

For instance, in July 2022, Bloom Diagnostics introduced the Bloom Inflammation Test, a semi-automated testing kit designed for the quantification of CRP levels in the blood. This single-use kit aids in the detection of inflammation within the body. The growth of the marketplace is expected to be further stimulated by the establishment of testing facilities. In June 2021, Trivitron Healthcare unveiled a mobile laboratory for COVID-19 diagnostics, enabling testing services in various regions of India, including rural, urban, and remote areas. This indigenous laboratory offers a range of tests, including CLIA/Elisa tests for inflammatory markers, such as a CRP, IL-6, and D-Dimer, as well as rapid antigen tests, RT-PCR tests, CLIA/Elisa Antibodies Tests IgM and IgG, and others.

North America held the largest revenue share of 39.42% in 2022 and is expected to maintain its share during the forecast period due to the increasing prevalence of cardiovascular diseases, a steady stream of product launches, presence of established market players, technological advancements, and well-developed healthcare infrastructure. Asia Pacific is projected to grow at the fastest CAGR of 0.49% from 2023 to 2030. The COVID-19 pandemic originated in China. Being the potential biomarker for determining the severity of the infection, the demand for CRP testing is expected to increase shortly. Key players operating in the global industry are constantly focusing on product launches and geographical expansion to maintain their presence.

C-Reactive Protein Testing Market Report Highlights:

  • Based on assay type, the immunoturbidimetric assay segment held the largest revenue share of 48.5% in 2024. Owing to the introduction of a highly sensitive, automated, and cost-effective immunoturbidimetric assay that offers a wide measuring range for accurately detecting the levels of CRP in samples
  • Based on detection ranges, the hs-CRP segment dominated the market in 2024 with a revenue share of approximately 42.80%. The hs-CRP features a broad detection range than that compared to the conventional CRP
  • Based on disease area type, the cardiovascular diseases segment dominated the market with the largest market share in 2024 and is anticipated to dominate the market throughout the forecast period. The increase in the prevalence of CVDs is the major factor contributing to the growth of the CRP testing market
  • The hospitals end-user segment dominated with a market share of 28.0% in 2024 due to the increased adoption of CRP testing in hospitals, particularly in response to the COVID-19 pandemic. This has led to a higher testing rate and contributed to the segment's growth
  • Furthermore, the marketplace is experiencing growth due to the increasing prevalence of chronic heart diseases and cancers. These conditions contribute significantly to the market's expansion as there is a rising demand for CRP testing in the diagnosis, management, and monitoring of these diseases

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Assay Type
    • 1.2.2. Detection Range
    • 1.2.3. Disease Type
    • 1.2.4. End Use
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. C-Reactive Protein Testing Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising incidence of chronic and infectious diseases
      • 3.3.1.2. Increasing demand for point-of-care diagnostics
      • 3.3.1.3. Growing demand for portable and automated C-reactive proteins
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Lower detection limit
      • 3.3.2.2. Limitations associated with C-reactive protein techniques
  • 3.4. C-Reactive Protein Testing Market Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. C-Reactive Protein Testing Market: Assay Type Estimates & Trend Analysis

  • 4.1. C-reactive Protein (CRP) Testing Market: Assay Type Movement Analysis
  • 4.2. Immunoturbidimetric Assay
    • 4.2.1. Immunoturbidimetric Assay Market, 2018 - 2030 (USD Million)
  • 4.3. ELISA
    • 4.3.1. ELISA Market, 2018 - 2030 (USD Million)
    • 4.3.2. Clinical ELISA
      • 4.3.2.1. Clinical ELISA Market, 2018 - 2030 (USD Million)
    • 4.3.3. Nonclinical ELISA
      • 4.3.3.1. Nonclinical ELISA Market, 2018 - 2030 (USD Million)
  • 4.4. Chemiluminescence Immunoassay
    • 4.4.1. Chemiluminescence Immunoassay Market, 2018 - 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. C-Reactive Protein Testing Market: Detection Range Estimates & Trend Analysis

  • 5.1. C-reactive Protein (CRP) Testing Market: Detection Range Movement Analysis
  • 5.2. High Sensitivity C-reactive Protein (hs-CRP)
    • 5.2.1. High Sensitivity C-reactive Protein (hs-CRP) Market, 2018 - 2030 (USD Million)
  • 5.3. Conventional CRP
    • 5.3.1. Conventional CRP Market, 2018 - 2030 (USD Million)
  • 5.4. Cardiac CRP (cCRP)
    • 5.4.1. Cardiac CRP (CCRP) Market, 2018 - 2030 (USD Million)

Chapter 6. C-Reactive Protein Testing Market Disease Area Estimates & Trend Analysis

  • 6.1. C-reactive Protein (CRP) Testing Market: Disease Area Movement Analysis
  • 6.2. Cardiovascular Diseases
    • 6.2.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 6.3. Cancer
    • 6.3.1. Cancer Market, 2018 - 2030 (USD Million)
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.5. Inflammatory Bowel Disease
    • 6.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 6.6. Endometriosis
    • 6.6.1. Endometriosis Market, 2018 - 2030 (USD Million)
  • 6.7. Lupus
    • 6.7.1. Lupus Market, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. C-Reactive Protein Testing Market End Use Estimates & Trend Analysis

  • 7.1. C-reactive Protein (CRP) Testing Market: End-use Movement Analysis
  • 7.2. Clinics
    • 7.2.1. Clinics Market, 2018 - 2030 (USD Million)
    • 7.2.2. Clinics, by entity
      • 7.2.2.1. Physician offices
        • 7.2.2.1.1. Physician Offices Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Small clinics
        • 7.2.2.2.1. Small Clinics Market, 2018 - 2030 (USD Million)
      • 7.2.2.3. Others
        • 7.2.2.3.1. Others Market, 2018 - 2030 (USD Million)
    • 7.2.3. Clinics, by setting
      • 7.2.3.1. Urban setting
        • 7.2.3.1.1. Urban Setting Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Rural settings
        • 7.2.3.2.1. Rural Settings Market, 2018 - 2030 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Market, 2018 - 2030 (USD Million)
    • 7.3.2. Urban setting
      • 7.3.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
    • 7.3.3. Rural settings
      • 7.3.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
  • 7.4. Laboratories
    • 7.4.1. Laboratories Market, 2018 - 2030 (USD Million)
    • 7.4.2. Urban setting
      • 7.4.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
    • 7.4.3. Rural settings
      • 7.4.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities Market, 2018 - 2030 (USD Million)
    • 7.5.2. Urban setting
      • 7.5.2.1. Urban Setting Market, 2018 - 2030 (USD Million)
    • 7.5.3. Rural settings
      • 7.5.3.1. Rural Settings Market, 2018 - 2030 (USD Million)
  • 7.6. Home
    • 7.6.1. Home Market, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. C-Reactive Protein Testing Market: Regional Estimates & Trend Analysis

  • 8.1. C-Reactive Protein Testing Market Share, By Region, 2024 & 2030, USD Million
  • 8.2. North America
    • 8.2.1. North America C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. UK C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. Germany C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. Australia C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. South Korea C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait C-Reactive Protein Testing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Company Heat Map Analysis
  • 9.4. Company Profiles
  • 9.5. Abbott
    • 9.5.1. Participant's Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments/ Strategic Initiatives
  • 9.6. Siemens Healthineers AG
    • 9.6.1. Participant's Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments/ Strategic Initiatives
  • 9.7. Danaher Corporation
    • 9.7.1. Participant's Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments/ Strategic Initiatives
  • 9.8. Quest Diagnostics
    • 9.8.1. Participant's Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments/ Strategic Initiatives
  • 9.9. Siemens Healthineers AG
    • 9.9.1. Participant's Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Developments/ Strategic Initiatives
  • 9.10. Abbott
    • 9.10.1. Participant's Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Developments/ Strategic Initiatives
  • 9.11. Merck KGaAA
    • 9.11.1. Participant's Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Developments/ Strategic Initiatives
  • 9.12. Zoetis
    • 9.12.1. Participant's Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Developments/ Strategic Initiatives
  • 9.13. F. Hoffmann-La Roche AG
    • 9.13.1. Participant's Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Developments/ Strategic Initiatives
  • 9.14. Ortho Clinical Diagnostics
    • 9.14.1. Participant's Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Developments/ Strategic Initiatives
  • 9.15. Thermo Fisher Scientific, Inc.
    • 9.15.1. Participant's Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Developments/ Strategic Initiatives
  • 9.16. HORIBA, Ltd
    • 9.16.1. Participant's Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Developments/ Strategic Initiatives
  • 9.17. Randox Laboratories Ltd.
    • 9.17.1. Participant's Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Developments/ Strategic Initiatives
  • 9.18. Boditech Med, Inc.
    • 9.18.1. Participant's Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Developments/ Strategic Initiatives
  • 9.19. Aidian
    • 9.19.1. Participant's Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Developments/ Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제